tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OKYO Stock Latest News

OKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain
Company AnnouncementsOKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain
3d ago
6K
OKYO
Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial
PremiumThe Fly
Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial
3d ago
OKYO
Okyo Pharma initiated with a Buy at B. Riley
PremiumThe Fly
Okyo Pharma initiated with a Buy at B. Riley
6d ago
OKYO
OKYO Pharma’s Chairman Increases Stake Amidst Phase 2 Trial Completion
PremiumCompany Announcements
OKYO Pharma’s Chairman Increases Stake Amidst Phase 2 Trial Completion
11d ago
6K
OKYO
Okyo Pharma chairman acquires 27,051 company shares
PremiumThe Fly
Okyo Pharma chairman acquires 27,051 company shares
11d ago
OKYO
OKYO Pharma’s Chairman Increases Stake with Recent Share Acquisition
PremiumCompany AnnouncementsOKYO Pharma’s Chairman Increases Stake with Recent Share Acquisition
23d ago
6K
OKYO
Okyo Pharma chairman acquires 82,018 company shares
Premium
The Fly
Okyo Pharma chairman acquires 82,018 company shares
23d ago
OKYO
OKYO Pharma to Present Urcosimod at OIS XV
Premium
Company Announcements
OKYO Pharma to Present Urcosimod at OIS XV
26d ago
6K
OKYO
OKYO Pharma to Present at BIO-Europe 2025 Highlighting Urcosimod Progress
PremiumCompany Announcements
OKYO Pharma to Present at BIO-Europe 2025 Highlighting Urcosimod Progress
2M ago
6K
OKYO
OKYO Pharma’s Chairman Increases Stake with New Share Acquisition
PremiumCompany Announcements
OKYO Pharma’s Chairman Increases Stake with New Share Acquisition
2M ago
6K
OKYO
Okyo Pharma chairman acquires 210,000 company shares
PremiumThe Fly
Okyo Pharma chairman acquires 210,000 company shares
2M ago
OKYO
OKYO Pharma Advances Urcosimod Clinical Trials for Neuropathic Corneal Pain
PremiumCompany Announcements
OKYO Pharma Advances Urcosimod Clinical Trials for Neuropathic Corneal Pain
3M ago
6K
OKYO
Okyo Pharma announces plans for next stage of development for urcosimod
PremiumThe FlyOkyo Pharma announces plans for next stage of development for urcosimod
3M ago
OKYO
Okyo Pharma initiated with a Buy at Lucid Capital
Premium
The Fly
Okyo Pharma initiated with a Buy at Lucid Capital
5M ago
OKYO
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development
Premium
Company Announcements
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development
5M ago
6K
OKYO
Okyo Pharma receives $1.9M in non-dilutive funding
PremiumThe Fly
Okyo Pharma receives $1.9M in non-dilutive funding
5M ago
OKYO
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation
PremiumRatings
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation
5M ago
OKYO
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
PremiumCompany Announcements
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
5M ago
6K
OKYO
Okyo Pharma reports Phase 2 clinical trial results for urcosimod
PremiumThe Fly
Okyo Pharma reports Phase 2 clinical trial results for urcosimod
5M ago
OKYO
OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention
PremiumCompany AnnouncementsOKYO Pharma CEO to Present Urcosimod Development at Bio International Convention
6M ago
6K
OKYO
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
Premium
Company Announcements
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
7M ago
6K
OKYO
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain
Premium
Company Announcements
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain
8M ago
6K
OKYO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >